Pembrolizumab plus chemotherapy followed by pembrolizumab in participants in Asia with early triple-negative breast cancer: An updated subgroup analysis of the KEYNOTE-522 randomized clinical trial
Yeon Hee Park, Rina Hui, Seock-Ah Im, Jin-Hee Ahn et autres
BACKGROUND: In KEYNOTE-522 (NCT03036488), addition of perioperative pembrolizumab to neoadjuvant chemotherapy significantly improved pathological complete response (pCR), event-free survival (EFS), and overall survival (OS) in early-stage triple-negative breast cancer (TNBC). pCR and EFS results in participants enrolled in Asia were consistent with …
kr, au, tw, jp, es, us, ch, de, pt, sg, gb (code pays fourni par la source)
0 citations
The Breast